Biosensors International Group Ltd. has acquired Devax Inc.’s Axxess bifurcation-stent assets in a deal worth $5.7 million.
The Morges, Switzerland-based company said the drug-eluting stent is a "natural complement" to its existing product portfolio. The device received CE Mark approval in August 2010.*
“We have a large and growing base of clinical data demonstrating the unique benefits of our BioMatrix [drug-eluting stents] for treating main-branch lesions. The Devax Axxess stent combines the same powerful combination of our proprietary Biolimus A9 drug and biodegradable polymer on a platform specifically designed for treating bifurcations safely, quickly and efficaciously,” said Biosensors CEO Jeffrey Jump in prepared remarks.
Lake Forest, Calif.-based Devax designed the Axxess stent system to treat the coronary artery plaques that form at the intersection of two blood vessels. These types of bifurcation lesions occur in an estimated 15 to 25 percent of patients undergoing percutaneous coronary interventions, according to Biosensors.